- AI-screener
- Securities US
- Blueprint Medicines Corporation
Blueprint Medicines Corporation
$127.90
-$0.20
-0.16%
5 Jun 20:00
$73.04
$128.24
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bullish sentiment is waning
3day with a yield of0.24%
Long
64.00%Short
36.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | ||
Support | ||
Cash flows |
Technical analysis
- Trend ClassTurning up
- Trend PowerSlow trend
- PatternAscending wedge
- EMA-20Bullish reversal2025-05-29 the price crossed up the moving average line and trying to form a short-term upside trend.
- EMA-50Bullish reversal2025-04-30 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.
- EMA-100Bullish reversal2025-05-01 the price crossed up the moving average line and trying to form a short-term upside trend.
- StochasticBullish RecoveryThe stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: main and signal line crossing.
- RSIBullish weakeningRSI indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.
- MACDBullish weakeningOscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 0.16% | 0.68% | $127.83 | $128.24 | 495.77M |
| Week | 26.40% | 1.11% | $100.57 | $128.24 | 8.87B |
| Month | 29.19% | 3.30% | $94.38 | $128.24 | 9.63B |
| 3 Months | 44.59% | 0.82% | $73.04 | $128.24 | 11.63B |
| 6 Months | 33.51% | 11.07% | $73.04 | $128.24 | 14.35B |
| Year | 22.71% | 0.64% | $73.04 | $128.24 | 18.36B |
| 3 years | 121.10% | 70.45% | $37.82 | $128.24 | 30.04B |
| 5 years | 80.23% | 94.92% | $37.82 | $128.24 | 43.11B |
| All time | 158.13% | 75.81% | $13.04 | $125.61 | 31.61B |
Volatility
| BPMC | By industry | |
|---|---|---|
| Yesterday | 2.04% | 1.28% |
| Week | 5.17% | 7.29% |
| Month | 8.77% | 10.86% |
| 3 Months | 17.71% | 20.88% |
| 6 Months | 26.92% | 29.79% |
| Year | 45.19% | 39.37% |
| 3 years | 94.71% | 85.40% |
| 5 years | 114.54% | 115.71% |
| All time | — | — |
- Sortino
- -0.06
- Sharpe
- -0.08
- Sterling
- -0.10
- Liquidity index
- 5.56
- Alpha
- -0.00030
- Beta
- 1.26
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$8.26B
Capitalization
64.58M
Shares outstanding
Health Care
Sector
Biotechnology
Industry
US09627Y1091
ISIN
100
Lot size
Ms. Kathryn Haviland
CEO
Website
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.